Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 548pembrolizumab 384Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × gp100 Melanoma Antigen × Clear all
NCT00960752 2021-08-13

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

M.D. Anderson Cancer Center

Phase 2 Completed
47 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT00003224 2014-11-20

Vaccine Therapy in Treating Patients With Metastatic Melanoma

University of Virginia

Phase 1 Completed
22 enrolled 14 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡